Developing novel vaccines to cure HIV infection

Read more
HTI immunogen: a new therapeutic vaccine against HIV
Approach

HTI immunogen: a new therapeutic vaccine against HIV

The HTI immunogen was discovered by Dr. Christian Brander, CSO of AELIX Therapeutics, and co-workers. It is based on the observation that T-cell responses to certain HIV regions are enriched in individuals with enhanced control of their HIV-infection. The HTI immunogen brings these beneficial regions together as a vaccine immunogen…

More
WHO WE ARE

Meet the team

AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.

More

Whats new?

March 20, 2023

Small team running a big project! We are proud to be a part of the AELIX success story that we hope will pave a path for an effective therapeutic vaccine against HIV infection.

Read more

February 22, 2023

AELIX has presented promising top-line results from the clinical study AELIX-003 at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).

Read more

February 15, 2023

We are excited to announce that the lead investigator, Beatriz Mothe and our CSO, Christian Brander, will present the promising topline results from our latest clinical trial AELIX-003 at the upcoming CROI conference. The data will be presented in a late-breaker session in the afternoon of February 21st.

Read more
More

Testimonials